Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating biomarkers in pulmonary arterial hypertension: update and future direction.
Pezzuto B, Badagliacca R, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD. Pezzuto B, et al. Among authors: vitulo p. J Heart Lung Transplant. 2015 Mar;34(3):282-305. doi: 10.1016/j.healun.2014.12.005. Epub 2014 Dec 23. J Heart Lung Transplant. 2015. PMID: 25682555 Review.
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, Paciocco G, Tuzzolino F, Martino L, Beretta M, Callari A, Amaducci A, Badagliacca R, Poscia R, Meloni F, Refini RM, Geri P, Baldi S, Ghio S, D'Alto M, Argiento P, Sofia M, Guardamagna M, Pezzuto B, Vizza CD. Vitulo P, et al. J Heart Lung Transplant. 2017 Feb;36(2):166-174. doi: 10.1016/j.healun.2016.04.010. Epub 2016 May 7. J Heart Lung Transplant. 2017. PMID: 27329400 Free article. Clinical Trial.
Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension.
Ghio S, D'Alto M, Badagliacca R, Vitulo P, Argiento P, Mulè M, Tuzzolino F, Scelsi L, Romeo E, Raineri C, Martino L, Tamburino C, Poscia R, Vizza CD. Ghio S, et al. Among authors: vitulo p. Int J Cardiol. 2017 Mar 1;230:53-58. doi: 10.1016/j.ijcard.2016.12.099. Epub 2016 Dec 21. Int J Cardiol. 2017. PMID: 28038821
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
Badagliacca R, D'Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, Casu G, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Galgano G, Greco A, Lombardi C, Manzi G, Mercurio V, Mulè M, Paciocco G, Papa S, Romeo E, Scelsi L, Stolfo D, Vitulo P, Naeije R, Vizza CD. Badagliacca R, et al. Among authors: vitulo p. Am J Respir Crit Care Med. 2021 Feb 15;203(4):484-492. doi: 10.1164/rccm.202004-1006OC. Am J Respir Crit Care Med. 2021. PMID: 32857597
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
D'Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, Correale M, Ghio S, Greco A, Lattanzio M, Mercurio V, Paciocco G, Papa S, Prediletto R, Romeo E, Russo MG, Tayar A, Vitulo P, Vizza CD, Golino P, Naeije R. D'Alto M, et al. Among authors: vitulo p. J Heart Lung Transplant. 2020 Dec;39(12):1389-1397. doi: 10.1016/j.healun.2020.08.016. Epub 2020 Aug 28. J Heart Lung Transplant. 2020. PMID: 32933828
Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH SOLUTION): proposal of a study protocol aimed to realize a validated risk score for early diagnosis.
Miotti C, D'Armini AM, Scardovi B, Ghio S, Sinagra G, Serra W, Romaniello A, Galgano G, Roncon L, D'Alto M, Giannazzo D, Vitulo P, Bongarzoni A, Ruzzolini M, Albera C, Casu G, Perazzolo Marra M, Pierdomenico SD, Luongo F, Manzi G, Papa S, Scoccia G, Cedrone N, Badagliacca R, Vizza CD. Miotti C, et al. Among authors: vitulo p. Minerva Cardiol Angiol. 2022 Oct;70(5):545-554. doi: 10.23736/S2724-5683.21.05575-7. Epub 2021 Mar 11. Minerva Cardiol Angiol. 2022. PMID: 33703863
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?
Badagliacca R, Papa S, D'Alto M, Ghio S, Agostoni P, Ameri P, Argiento P, Brunetti ND, Casamassima V, Casu G, Cedrone N, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Famoso G, Galgano G, Greco A, Lombardi CM, Manzi G, Madonna R, Mercurio V, Mulè M, Paciocco G, Romaniello A, Romeo E, Scelsi L, Serra W, Stolfo D, Toma M, Vatrano M, Vitulo P, Vizza CD; italian Pulmonary Hypertension NETwork (iPHNET). Badagliacca R, et al. Among authors: vitulo p. Eur Respir J. 2022 Oct 6;60(4):2102276. doi: 10.1183/13993003.02276-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35301247 Free PMC article.
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G; REPLACE investigators. Hoeper MM, et al. Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
418 results